SI1551390T1 - Formulacija, ki obsega avermektine/milbemicine in levamisol v pirolidonskem topilu - Google Patents

Formulacija, ki obsega avermektine/milbemicine in levamisol v pirolidonskem topilu

Info

Publication number
SI1551390T1
SI1551390T1 SI200332354T SI200332354T SI1551390T1 SI 1551390 T1 SI1551390 T1 SI 1551390T1 SI 200332354 T SI200332354 T SI 200332354T SI 200332354 T SI200332354 T SI 200332354T SI 1551390 T1 SI1551390 T1 SI 1551390T1
Authority
SI
Slovenia
Prior art keywords
milbemycins
avermectins
levamisole
formulation
pyrrolidone solvent
Prior art date
Application number
SI200332354T
Other languages
English (en)
Inventor
Robert William Lachlan Holmes
Majid Hameed Abdul Razzak (Dr)
Kour Chand Jindal (Dr)
Sen Nilendu
Original Assignee
Merial Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30768277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1551390(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Limited filed Critical Merial Limited
Publication of SI1551390T1 publication Critical patent/SI1551390T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
SI200332354T 2002-07-19 2003-07-21 Formulacija, ki obsega avermektine/milbemicine in levamisol v pirolidonskem topilu SI1551390T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ520295A NZ520295A (en) 2002-07-19 2002-07-19 Anthelmintic formulations comprising levamisole and either an avermectin or milbemycin
PCT/NZ2003/000157 WO2004009080A1 (en) 2002-07-19 2003-07-21 Levamisole, Avermectins or similar in pyrrolidone solvent
EP03741701.1A EP1551390B1 (en) 2002-07-19 2003-07-21 Formulation comprising avermectins / milbemycins and levamisole in a pyrrolidone solvent

Publications (1)

Publication Number Publication Date
SI1551390T1 true SI1551390T1 (sl) 2014-07-31

Family

ID=30768277

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332354T SI1551390T1 (sl) 2002-07-19 2003-07-21 Formulacija, ki obsega avermektine/milbemicine in levamisol v pirolidonskem topilu

Country Status (8)

Country Link
US (1) US20060128641A1 (sl)
EP (1) EP1551390B1 (sl)
AU (2) AU2003281472B2 (sl)
BR (1) BRPI0312814B1 (sl)
DK (1) DK1551390T3 (sl)
NZ (1) NZ520295A (sl)
SI (1) SI1551390T1 (sl)
WO (1) WO2004009080A1 (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82359C2 (uk) * 2003-04-03 2008-04-10 Schering Plough Ltd Композиція (варіанти) і спосіб лікування мікробних і паразитних інфекцій у великої рогатої худоби і інших тварин
DK1796692T3 (da) * 2004-09-09 2012-08-13 Warburton Technology Ltd Sporelementer
WO2006117641A2 (en) 2005-04-29 2006-11-09 Springboard Retail Networks Licensing Srl Enabling and managing ordering information within a network
TWI444140B (zh) * 2005-11-18 2014-07-11 Cheminova As 艾維菌素類之水包油調配物
BRPI0506279B1 (pt) * 2005-12-16 2018-01-09 Npa - Núcleo De Pesquisas Aplicadas Ltda Composição sinergística de antihelmínticos e endectocidas
NZ552040A (en) * 2006-12-13 2009-04-30 Bomac Research Ltd Veterinary formulation comprising an anthelmintic compound and glyceryl acetate
MX2010005685A (es) * 2007-11-26 2010-09-28 Merial Ltd Sistemas de solventes para formulaciones de vaciado determinado para combatir parasitos.
AU2013201461B2 (en) * 2007-11-26 2015-10-29 Boehringer Ingelheim Animal Health USA Inc. Solvent systems for pour-on formulations for combating parasites
UA108641C2 (uk) 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
US20110281920A1 (en) 2010-05-12 2011-11-17 Robert Holmes Injectable parasiticidal formulations of levamisole and macrocyclic lactones
AU2016201743B2 (en) * 2010-05-12 2017-10-19 Boehringer Ingelheim Animal Health USA Inc. Injectable parasiticidal formulations of levamisole and macrocyclic lactones
AR081970A1 (es) * 2010-06-24 2012-10-31 Intervet Int Bv Formulacion inyectable de una lactona macrociclica y levamisol, formulacion y uso veterinario
AU2011338573B2 (en) 2010-12-07 2016-07-28 Boehringer Ingelheim Animal Health USA Inc. Topical combination formulations of macrocyclic lactones with synthetic pyrethroids
WO2012177151A1 (en) * 2011-06-23 2012-12-27 Bayer New Zealand Limited Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation
NZ594610A (en) * 2011-08-16 2013-03-28 Virbac New Zealand Ltd Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
EP3749096A1 (en) 2018-02-08 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
AU2020208145B2 (en) * 2019-01-16 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773422A (en) * 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
WO1998006407A1 (en) * 1996-07-30 1998-02-19 Ashmont Holdings Limited Anthelmintic formulations
US6426333B1 (en) * 1996-09-19 2002-07-30 Merial Spot-on formulations for combating parasites
US6054140A (en) * 1997-03-21 2000-04-25 Biogenesis S.A. Long acting injectable parasiticidal composition and the process for its preparation
WO2000074489A1 (en) * 1999-06-04 2000-12-14 Nufarm Limited Stable biocidal compositions
US6780885B1 (en) * 2000-01-14 2004-08-24 Idexx Laboratories, Inc. Formulations and methods for administration of pharmacologically or biologically active compounds
US6340672B1 (en) * 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation

Also Published As

Publication number Publication date
AU2005200099A1 (en) 2005-03-17
AU2003281472B2 (en) 2008-07-24
AU2003281472A1 (en) 2004-02-09
DK1551390T3 (da) 2014-04-28
NZ520295A (en) 2005-04-29
US20060128641A1 (en) 2006-06-15
BR0312814A (pt) 2005-04-19
WO2004009080A1 (en) 2004-01-29
EP1551390A1 (en) 2005-07-13
BRPI0312814B1 (pt) 2017-06-06
EP1551390A4 (en) 2008-11-05
EP1551390B1 (en) 2014-04-02

Similar Documents

Publication Publication Date Title
SI1551390T1 (sl) Formulacija, ki obsega avermektine/milbemicine in levamisol v pirolidonskem topilu
IL236190B (en) A preparation containing amikacin and a lipid component
HK1091724A1 (en) Formulations comprising ecteinascidin and a disaccharide
AP2083A (en) Topical formulations comprising a 1-N-arylprazole derivative and a formamidine
AU2001253618A1 (en) Flavopiridol drug combinations and methods with reduced side effects
GB0414825D0 (en) Gel formulations and uses thereof
AU2003201810A1 (en) Method for reducing morbidity and mortality in critically ill patients
AU2003234564A1 (en) Side hole in catheter
AU2002953176A0 (en) Exercise device and method
AU2003222823A8 (en) Physiologically compatible, phospholipid-containing, stable and hard matrix
AU2003296369A1 (en) Imminoamines and preparation thereof
AU2003268116A1 (en) Method for reducing morbidity and mortality in critically ill patients
AU2003210704A1 (en) Lottery game and system
PL369670A1 (en) Combinations comprising epothilones and anti-metabolites
AU2003289929A1 (en) Transmucosal and transdermal medicaments with an improved active ingredient absorption
GB0322183D0 (en) Ball and game
GB0317877D0 (en) Pharmaceutical combinations and formulations with improved stability
AU2003216989A1 (en) Improvements in and relating to marking
AU2003236665A1 (en) 2-thio-substituted imidazole derivatives and their use in pharmaceutics
AU2003263895A8 (en) Contraceptive methods and formulations
AU2003277025A1 (en) Ink compositions and formulation methods therefor
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003292611A1 (en) Game device and game progressing method using the same
AU2003217267A1 (en) Lottery game and system
AU2003235887A1 (en) Bislactone derivative and use thereof in medicinal composition